Interleukin-2 fusion protein: An investigational therapy for interleukin-2 receptor expressing malignancies

European Journal of Cancer Part A

Volumn 33, Issue SUPPL. 1, 1997, Pages

  Nichols, J ^a   Foss, F ^b   Kuzel, T M ^c   LeMaistre, C F ^d   Platanias, L ^e   Ratain, M J ^f   Rook, A ^g   Saleh, M ^h   Schwartz, G ⁱ  

^a Seragen Inc   (United States)

^b BOSTON UNIVERSITY   (United States)

^c NORTHWESTERN UNIVERSITY   (United States)

^d South Texas Cancer Institute   (United States)

^e LOYOLA UNIVERSITY CHICAGO   (United States)

^f UNIVERSITY OF CHICAGO   (United States)

^g UNIVERSITY OF PENNSYLVANIA   (United States)

^h UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

ⁱ BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

Clinical trial; CTCL; DAB389IL 2; Fusion protein; IL 2; IL 2R; Lymphoma

Indexed keywords

DIPHTHERIA TOXIN; HYBRID PROTEIN; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR;

CLINICAL TRIAL; CONFERENCE PAPER; HUMAN; LEUKEMIA; LYMPHOMA; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL;

EID: 0030888194     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(96)00327-9     Document Type: Conference Paper

References (27)

1. 389IL-2): fragment G-sequences required for the delivery of fragment A to the cytosol of target cells. J Biol Chem 1990, 265, 11885-11889.
2. Waters CA, Schimke PA, Snider CE, et al. Interleukin-2 receptor targeted cytotoxicity. Receptor binding requirements for entry of a diphtheria toxin-related interleukin-2 fusion protein into cells. Eur J Immunol 1990, 20, 785-791.
3. Bacha P, Forte SE, McCarthy DM, et al. Impact of interleukin-2 receptor targeted cytotoxins on a unique model of murine interleukin-2 receptor-expressing malignancy, Int J Cancer 1991, 49, 96-101.
4. Takeshita T, Asao H, Ohtani K, et al. Cloning of the γ chain of the IL-2 receptor. Science 1992, 257, 379.
5. Weismann AM, Harford JB, Svetlik PB, et al. Only high-affinity receptors for interleukin 2 mediate internalization of ligand. Proc Natl Acad Sci USA 1986, 83, 1463-1466.
6. Siegel JP, Sharon M, Smith PL, et al. The IL-2 receptor bet chain (p70): role in mediating signals for LAK, NK and proliferative activities. Science 1987, 238, 75-78.
7. Tsudo M, Goldman CK, Bongiovanni KF, et al. The p75 peptide is the receptor for interleukin-2 expressed on large granular lymphocytes and is responsible for the interleukin-2 activation of these cells. Proc Natl Acad Sci USA 1987, 84, 5394-5398.
8. Lowenthal JW, Macdonald HR, Iacopetta BJ. Intracellular pathway of interleukin 2 following receptor-mediated endocytosis. Eur J Immunol 1986, 16, 1461-1463.
9. Waldmann TA. The structure, function and expression of interleukin-2 receptors on normal and malignant lymphocytes. Science 1986, 232, 727-731.
10. Waldmann TA, Goldman CK, Robb RJ, et al. Expression of interleukin-2 receptors on activated human β cells. J Exp Med 1984, 160, 1460-1466.
11. Strauchen and Breakstone. IL-2 receptor expression in human lymphoid lesions: immunohistochemical study of 166 cases. Am J Pathol 1987, 126, 506-512.
12. Wood GS. Lymphocyte activation in cutaneous T-cell lymphoma. The Society for Investigative Dermatology 1995, 105, 1 (Suppl.), 1055-1095.
13. Vonderheid EC, Diamond LW, Van Vloten WA, et al. Lymph node classification systems in cutaneous T-cell lymphoma. Cancer 1994, 73, 207-218.
14. Joly P, Charlotte F, Leibowitch M, et al. Cutaneous lymphomas other than mycosis fungoides: follow-up study of 52 patients. J Clin Oncol 1991, 9, 1994-2991.
15. Schecter GP, et al. Evaluation of circulating malignant cells provides prognostic information in cutaneous T-cell lymphoma. Blood 1987, 69, 841-849.
16. Bunn PA, Huberman M, et al. Prospective staging evaluation of patients with cutaneous T-cell lymphoma: demonstration of high frequency of extra-cutaneous dissemination. Ann Intern Med 1980, 93, 223-230.
17. Sausville E, et al. Histologic assessment of lymph nodes in mycosis fungoides/sezary syndrome (cutaneous T-cell lymphoma). Clinical correlations and prognostic import of a new classification system. Human Pathol 1985, 16, 1098-1109.
18. Lynch J, Linville I, et al. Prognostic implications of evaluation for lymph node involvement by T-cell antigen receptor gene rearrangement in mycosis fungoides. Blood 1992, 79, 3293-3299.
19. Bakels V, van Dostveen J, et al. Diagnostic and prognostic significance of clonal T-cell receptor β-gene rearrangements in lymph nodes of patients with mycosis fungoides. J Pathol 1993, 170, 249-255.
20. Hamminga L, Hermans J, Noordijk EM, et al. Cutaneous T-cell lymphoma: Clinicopathological relationships, therapy and survival in ninety-two patients. Br J Dermatol 1982, 107, 145-155.
21. Sausville E, Eddy J, et al. Histopathologic staging at initial diagnosis of mycosis fungoides and Sezary syndrome: definition of three distinctive prognostic groups. Ann Intern Med 1988, 109, 372-382.
22. Vonderheid EC, Diamond LW, Van Vloten WA, et al. Lymph node classification systems in cutaneous T-cell lymphoma. Evidence for the utility of the working formulation of non-Hodgkin's lymphomas for clinical usage. Cancer 1994, 73, 207-218.
23. Epstein E, Levin D, Croft J, et al. Mycosis fungoides: survival, prognostic features, response to therapy and autopsy findings. Medicine 1972, 51, 61-72.
24. Holloway KB. Therapeutic alternatives in cutaneous T-cell lymphoma: J Am Acad Dermatol 1992, 27, 367-378.
25. Abel E, Wood G, Hoppe R. Mycosis fungoides: clinical and histological features, staging, evaluation and approach to treatment. CA Cancer J Clin 1993, 43, 93-115.
26. Springer et al. International symposium in cutaneous T-cell lymphoma. Am J Clin Oncol 1991, 24, 136-138.
27. Waters CA, Nylen P, Parker KC, et al. Rationale for the use of IL-2 receptor-targeted fusion toxins in patients with Hodgkin's disease, non-Hodgkin's lymphoma and cutaneous T-cell lymphoma. AACR Special Conference, 7-11 November, 1993, Abstract A6.